Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 3 · 60%Low 0 · 0%Moderate 1 · 20%High 0 · 0%

Bevacizumab plus chemotherapy vs chemotherapy alone

Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer

Bevacizumab plus chemotherapy probably leads to higher specificadverse events: gastrointestinal perforations or fistulae compared with chemotherapy (moderate certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 18 [2.42, 133.67]
1 study · 440 participants
Moderate

Pazopanib plus lapatinib vs lapatinib

Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether pazopanib plus lapatinib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 2 [0.19, 21.59]
1 study · 152 participants
Very low

Pazopanib vs lapatinib

Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether pazopanib changes specific adverse events: gastrointestinal perforations or fistulae compared with lapatinib (very low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 1.03 [0.07, 16.12]
1 study · 150 participants
Very low

Cediranib plus chemotherapy vs placebo plus chemotherapy

Specific adverse events: gastrointestinal perforations or fistulae · women with persistent, recurrent, or metastatic cervical cancer

It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: gastrointestinal perforations or fistulae compared with placebo plus chemotherapy (very low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 3.27 [0.14, 77.57]
1 study · 67 participants
Very low

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found